Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (TOP2A)

References

• Yokoi A, Matsuzaki J, Yamamoto Y, et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun. 2018 Oct 17;9(1):4319.
   PubMedGoogle Scholar
• Pisanic TR 2nd, Cope LM, Lin SF, et al. Methylomic analysis of ovarian cancers identifies tumor-specific alterations readily detectable in early precursor Lesions. Clin Cancer Res off J Am Assoc Cancer Res. 2018 Dec 15;24(24):6536–6547.
   PubMed Web of Science ®Google Scholar
• Shah HK, Bhat MA, Sharma T, et al. Delineating potential transcriptomic association with organochlorine pesticides in the etiology of epithelial ovarian cancer. Open Biochem J. 2018;12(1):16–28.
   PubMedGoogle Scholar
• Heindl A, Khan AM, Rodrigues DN, et al. Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. Nat Commun. 2018 Sep 25;9(1):3917.
   PubMedGoogle Scholar
• Beermann J, Piccoli MT, Viereck J, et al. RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016 Oct;96(4):1297–1325.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Qi GT, Zhang XM, et al. lncRNA RHPN1-AS1 promotes the progression of endometrial cancer through the activation of ERK/MAPK pathway. J Obstet Gynaecol Res. 2020 Nov 9;47(2):533–543.
   PubMed Web of Science ®Google Scholar
• Dutta A, Roy A, Chatterjee S. Long noncoding RNAs in cancer immunity: a new avenue in drug discovery. Drug Discov Today. 2020 Aug 20;26(1):264–272.
   PubMed Web of Science ®Google Scholar
• Abbastabar M, Sarfi M, Golestani A, et al. lncRNA involvement in hepatocellular carcinoma metastasis and prognosis. EXCLI J. 2018;17:900–913.
   PubMed Web of Science ®Google Scholar
• Chen Z, Huang J, Feng Y, et al. Profiling of specific long non-coding RNA signatures identifies ST8SIA6-AS1 AS a novel target for breast cancer. J Gene Med. 2020 Oct 10; e3286. DOI:10.1002/jgm.3286.
   Web of Science ®Google Scholar
• Zheng W, Li H, Zhang H, et al. Long noncoding RNA RHPN1-AS1 promotes colorectal cancer progression via targeting miR-7-5p/OGT axis. Cancer Cell Int. 2020;20(1):54.
   PubMed Web of Science ®Google Scholar
• Ding L, Wang L, Li Z, et al. The positive feedback loop of RHPN1-AS1/miR-1299/ETS1 accelerates the deterioration of gastric cancer. Biomed Pharmacothe. 2020Apr;124:109848.
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu T, Zhang X, et al. lncRNA RHPN1-AS1 promotes ovarian cancer growth and invasiveness through inhibiting miR-1299. Onco Targets Ther. 2020;13:5337–5344.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yang T, Ji J, et al. RHPN1-AS1 promotes cell proliferation and migration via miR-665/Akt3 in ovarian cancer. Cancer Gene Ther. 2020 May 27;28(1–2):33–41.
   PubMed Web of Science ®Google Scholar
• Wang J, Ding W, Xu Y, et al. Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1. Aging (Albany NY). 2020 Mar 12;12(5):4558–4572.
   PubMedGoogle Scholar
• Qian W, Ren Z, Lu X. Knockdown of long non-coding RNA TUG1 suppresses nasopharyngeal carcinoma progression by inhibiting epithelial-mesenchymal transition (EMT) via the promotion of miR-384. Biochem Biophys Res Commun. 2019 Jan 29;509(1):56–63.
   PubMed Web of Science ®Google Scholar
• Duan G, Zhang C, Xu C, et al. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR‑34a/cyclin D1 axis. Int J Oncol. 2019 Jan;54(1):17–28.
   PubMed Web of Science ®Google Scholar
• Guan YX, Zhang MZ, Chen XZ, et al. Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR-495. J Cell Biochem. 2018 Nov;119(10):7971–7981.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhang H, Long J, et al. SNHG7 functions as an oncogene in cervical cancer by sponging miR-485-5p to modulate JUND expression. Onco Targets Ther. 2020;13:1677–1689.
   PubMed Web of Science ®Google Scholar
• Peng Y, Leng W, Duan S, et al. Long noncoding RNA BLACAT1 is overexpressed in hepatocellular carcinoma and its downregulation suppressed cancer cell development through endogenously competing against hsa-miR-485-5p. Biomed Pharmacothe. 2019Aug;116:109027.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu J, Qian X, et al. miR-485-5p improves the progression of ovarian cancer by targeting SRC in vitro and in vivo. Neoplasma. 2020 Sep;67(5):1022–1031.
   PubMed Web of Science ®Google Scholar
• Xing S, Zhang Y, Zhang J. LINC01224 exhibits cancer-promoting activity in epithelial ovarian cancer through microRNA-485-5p-mediated PAK4 upregulation. Onco Targets Ther. 2020;13:5643–5655.
   PubMed Web of Science ®Google Scholar
• Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J. 1994 Nov 1;303(Pt 3):681–695.
   PubMed Web of Science ®Google Scholar
• Woessner RD, Mattern MR, Mirabelli CK, et al. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991 Apr;2(4):209–214.
   PubMedGoogle Scholar
• Pei YF, Yin XM, Liu XQ. TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway. Biochimica Et Biophysica Acta Mol Basis Dis. 2018 Jan;1864(1):197–207.
   PubMed Web of Science ®Google Scholar
• Zhang R, Xu J, Zhao J, et al. Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem. 2018 Sep;119(9):7256–7263.
   PubMed Web of Science ®Google Scholar
• Wang B, Shen Y, Zou Y, et al. TOP2A promotes cell migration, invasion and epithelial-mesenchymal transition in cervical cancer via activating the PI3K/AKT signaling. Cancer Manag Res. 2020;12:3807–3814.
   PubMed Web of Science ®Google Scholar
• Cui Y, Pu R, Ye J, et al. LncRNA FAM230B Promotes Gastric Cancer Growth and Metastasis by Regulating the miR-27a-5p/TOP2A Axis. Dig Dis Sci. 2020 Sep 10. DOI:10.1007/s10620-020-06581-z.
   Web of Science ®Google Scholar
• Gao Y, Zhao H, Ren M, et al. TOP2A promotes tumorigenesis of high-grade serous ovarian cancer by regulating the TGF-β/Smad pathway. J Cancer. 2020;11(14):4181–4192.
   PubMed Web of Science ®Google Scholar
• Ghisoni E, Maggiorotto F, Borella F, et al. TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. J Ovarian Res. 2019 Feb 13;12(1):17.
   PubMedGoogle Scholar
• Erriquez J, Becco P, Olivero M, et al. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol. 2015 Sep;138(3):627–633.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu W, Levy DE. Nuclear and cytoplasmic mRNA quantification by SYBR green based real-time RT-PCR. Methods. 2006 Aug;39(4):356–362.
   PubMed Web of Science ®Google Scholar
• Hu H, Liu Z, Liu C. Correlation of OPN gene expression with proliferation and apoptosis of ovarian cancer cells and prognosis of patients. Oncol Lett. 2019 Mar;17(3):2788–2794.
   PubMed Web of Science ®Google Scholar
• Diermeier-Daucher S, Clarke ST, Hill D, et al. Cell type specific applicability of 5-ethynyl-2ʹ-deoxyuridine (EdU) for dynamic proliferation assessment in flow cytometry. Cytometry A. 2009 Jun;75(6):535–546.
   PubMedGoogle Scholar
• Zhang W, Liang Z. [Comparison between annexin V-FITC/PI and Hoechst33342/PI double stainings in the detection of apoptosis by flow cytometry]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Nov;30(11):1209–1212.
   PubMedGoogle Scholar
• Si X, Xu F, Xu F, et al. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway. Biomed Pharmacothe. 2020Mar;123:109717.
   PubMed Web of Science ®Google Scholar
• Marshall J. Transwell(®) invasion assays. Methods Mol Biol. 2011;769:97–110.
   PubMedGoogle Scholar
• Wang X, Yang B, She Y, et al. The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 2018 Sep;119(9):7790–7799.
   PubMed Web of Science ®Google Scholar
• Zeng S, Liu A, Dai L, et al. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC Cancer. 2019 Jun 19;19(1):604.
   PubMedGoogle Scholar
• Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, et al. TOP2A amplification and overexpression in hepatocellular carcinoma tissues. Biomed Res Int. 2015;2015:381602.
   PubMed Web of Science ®Google Scholar
• Jain M, Zhang L, He M, et al. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013 Jun;20(3):361–370.
   PubMed Web of Science ®Google Scholar
• Chen D, Maruschke M, Hakenberg O, et al. TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology. 2017 Apr;102:265. e1-265.e7.
   PubMed Web of Science ®Google Scholar
• Cai H, Shao B, Zhou Y, et al. High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis. Oncol Lett. 2020 Nov;20(5):232.
   PubMed Web of Science ®Google Scholar
• Lan J, Huang HY, Lee SW, et al. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumour Biol. 2014 Jan;35(1):179–187.
   PubMedGoogle Scholar
• Qiao HF, Liu YL, You J, et al. G-5555 synergized miR-485-5p to alleviate cisplatin resistance in ovarian cancer cells via Pi3k/Akt signaling pathway. J Reprod Immunol. 2020Aug;140:103129.
   PubMed Web of Science ®Google Scholar
• Yang Y, Jiang Y, Wan Y, et al. UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis. Tumour Biol. 2016 Aug;37(8):10633–10641.
   PubMedGoogle Scholar
• Liang D, Liu H, Yang Q, et al. Long noncoding RNA RHPN1-AS1, induced by KDM5B, is involved in breast cancer via sponging miR-6884-5p. J Cell Biochem. 2020 Jan 31. DOI:10.1002/jcb.29645.
   Web of Science ®Google Scholar
• Zhang XJ, Qi GT, Zhang XM, et al. lncRNA RHPN1-AS1 promotes the progression of endometrial cancer through the activation of ERK/MAPK pathway. J Obstet Gynaecol Res. 2021 Feb;47(2):533–543.
   PubMed Web of Science ®Google Scholar
• Cui P, Su J, Li Q, et al. LncRNA RHPN1-AS1 targeting miR-625/REG3A promotes cell proliferation and invasion of glioma cells. Onco Targets Ther. 2019;12:7911–7921.
   PubMed Web of Science ®Google Scholar
• Fen H, Hongmin Z, Wei W, et al. RHPN1-AS1 drives the progression of hepatocellular carcinoma via regulating miR-596/IGF2BP2 Axis. Curr Pharm Des. 2020;25(43):4630–4640.
   PubMed Web of Science ®Google Scholar
• Li G, Kong Q. LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/Raf1 axis. Biol Res. 2019 Dec 23;52(1):61.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li L, Hu H, et al. Circ-HIPK2 accelerates cell apoptosis and autophagy in myocardial oxidative injury by sponging miR-485-5p and targeting ATG101. J Cardiovasc Pharmacol. 2020 Oct;76(4):427–436.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang S, Shi P, et al. MiR-485-5p promotes neuron survival through mediating Rac1/Notch2 signaling pathway after Cerebral Ischemia/Reperfusion. Curr Neurovasc Res. 2020;17(3):259–266.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Shoorei H, Taheri M. Non-coding RNAs are involved in the response to oxidative stress. Biomed Pharmacothe. 2020Jul;127:110228.
   PubMed Web of Science ®Google Scholar
• Shindo-Okada N, Nagahara H, Yamaizumi Z, et al. The antibiotic, L-beta-(5-hydroxy-2-pyridyl)-alanine specif ically inhibits growth of the NIH3T3 cells transformed by activated human c-Ha-ras and induces formation of flat revertant cells. Nucleic Acids Symp Ser. 1988;19:129–130.
   PubMedGoogle Scholar
• Labbé DP, Sweeney CJ, Brown M, et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res off J Am Assoc Cancer Res. 2017 Nov 15;23(22):7072–7083.
   PubMed Web of Science ®Google Scholar